See more : HEARTSEED INC (219A.T) Income Statement Analysis – Financial Results
Complete financial analysis of OrganiGram Holdings Inc. (OGI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OrganiGram Holdings Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Population Health Investment Co., Inc. (PHICU) Income Statement Analysis – Financial Results
- Kirkland Lake Gold Ltd. (KL) Income Statement Analysis – Financial Results
- Welspun Enterprises Limited (WELENT.BO) Income Statement Analysis – Financial Results
- The Trendlines Group Ltd. (TRNLY) Income Statement Analysis – Financial Results
- New Talisman Gold Mines Limited (NTL.NZ) Income Statement Analysis – Financial Results
OrganiGram Holdings Inc. (OGI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.organigram.ca
About OrganiGram Holdings Inc.
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 159.84M | 149.21M | 145.81M | 79.16M | 86.80M | 80.41M | 12.43M | 5.71M | 6.13M | 986.68K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 112.32M | 114.13M | 114.24M | 107.56M | 143.29M | 31.94M | 39.20M | 8.84M | 813.38K | 339.51K | 274.91K | 0.00 | 0.00 |
| Gross Profit | 47.52M | 35.07M | 31.57M | -28.40M | -56.49M | 48.47M | -26.78M | -3.13M | 5.31M | 647.17K | -274.91K | 0.00 | 0.00 |
| Gross Profit Ratio | 29.73% | 23.51% | 21.65% | -35.87% | -65.08% | 60.28% | -215.42% | -54.73% | 86.73% | 65.59% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.20M | 12.19M | 5.96M | 3.45M | 1.27M | 409.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 48.29M | 48.95M | 42.35M | 30.72M | 29.94M | 26.67M | 9.27M | 4.78M | 2.31M | 1.76M | 66.77K | 318.91K | 140.16K |
| Selling & Marketing | 19.85M | 17.86M | 16.86M | 15.81M | 16.53M | 14.63M | 6.30M | 2.85M | 1.76M | 720.97K | 181.44K | 0.00 | 0.00 |
| SG&A | 68.14M | 71.68M | 59.21M | 46.52M | 46.47M | 41.30M | 15.57M | 7.62M | 4.07M | 2.49M | 66.77K | 318.91K | 140.16K |
| Other Expenses | 3.85M | 0.00 | 5.15M | -5.53M | -6.37M | 664.00K | 509.00K | 416.36K | 0.00 | 0.00 | 0.00 | 56.33K | 0.00 |
| Operating Expenses | 83.20M | 271.48M | 70.32M | 44.44M | 41.37M | 42.37M | 16.08M | 8.04M | 4.07M | 2.49M | 66.77K | 375.25K | 140.16K |
| Cost & Expenses | 195.51M | 385.61M | 184.56M | 152.00M | 184.65M | 74.31M | -23.99M | 16.88M | 4.88M | 2.15M | 66.77K | 375.25K | 140.16K |
| Interest Income | 0.00 | 3.69M | 1.49M | 854.00K | 308.00K | 662.00K | 0.00 | 9.87K | 0.00 | 0.00 | 996.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 277.85K | 429.00K | 2.96M | 6.01M | 9.67M | 10.09M | 273.87K | 436.37K | 115.41K | 996.00 | 0.00 | -140.16K |
| Depreciation & Amortization | 12.08M | 23.42M | 24.91M | 31.03M | 17.96M | 8.90M | 3.53M | 1.56M | 785.59K | 414.80K | 173.53K | 0.00 | 0.00 |
| EBITDA | -23.59M | -25.37M | -15.21M | -42.92M | -122.66M | 12.70M | 41.40M | -9.62M | 2.03M | -746.65K | 106.76K | -375.25K | -140.16K |
| EBITDA Ratio | -14.76% | -17.00% | -10.43% | -54.22% | -93.42% | 17.09% | 321.38% | -168.30% | 33.15% | -75.42% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.67M | -48.79M | -38.75M | -91.82M | -145.51M | 5.49M | 36.42M | -11.17M | 1.25M | -1.16M | -66.77K | -375.25K | -140.16K |
| Operating Income Ratio | -22.32% | -32.70% | -26.58% | -115.99% | -167.65% | 6.82% | 292.99% | -195.44% | 20.33% | -117.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.77M | -184.21M | 24.38M | -38.88M | -46.98M | -11.36M | -8.64M | 211.32K | -398.97K | -117.90K | 1.38M | 0.00 | 0.00 |
| Income Before Tax | -45.44M | -233.00M | -14.37M | -130.70M | -146.63M | -5.88M | 27.78M | -10.89M | 846.66K | -1.28M | -239.31K | -375.25K | 0.00 |
| Income Before Tax Ratio | -28.43% | -156.16% | -9.86% | -165.11% | -168.94% | -7.31% | 223.49% | -190.59% | 13.82% | -129.41% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.52M | -88.00K | 1.84M | -10.47M | 3.63M | 5.65M | -550.94K | -37.41K | 2.49K | 171.54K | 0.00 | 140.16K |
| Net Income | -45.44M | -229.48M | -14.28M | -132.55M | -136.16M | -9.50M | 20.51M | -10.89M | 846.66K | -1.28M | -239.31K | -375.25K | -140.16K |
| Net Income Ratio | -28.43% | -153.80% | -9.80% | -167.43% | -156.87% | -11.82% | 165.04% | -190.59% | 13.82% | -129.41% | 0.00% | 0.00% | 0.00% |
| EPS | -0.44 | -2.82 | -0.18 | -2.07 | -3.15 | -0.27 | 0.68 | -0.45 | 0.06 | -0.10 | -0.12 | -0.18 | -0.08 |
| EPS Diluted | -0.42 | -2.82 | -0.18 | -2.07 | -3.15 | -0.27 | 0.65 | -0.45 | 0.06 | -0.10 | -0.12 | -0.18 | -0.08 |
| Weighted Avg Shares Out | 103.80M | 81.29M | 77.23M | 64.03M | 43.17M | 35.23M | 30.14M | 24.30M | 14.67M | 13.10M | 2.07M | 2.07M | 1.75M |
| Weighted Avg Shares Out (Dil) | 108.38M | 81.29M | 77.23M | 64.03M | 43.17M | 35.23M | 31.72M | 24.30M | 14.67M | 13.10M | 2.07M | 2.07M | 1.75M |
Cannabis stocks struggle as Canada marks five years of legal recreational use
Tuesday, October 17, 2023 marks five years since recreational cannabis was legalized in Canada and it's been tough going for operators in the budding sector. Industry players have had to contend with oversaturation, competition from the black market, limited opportunities...
Organigram Is A Great Stock For Value Investors
I have been bullish on Organigram for quite some time, but it has dropped significantly. The stock is ridiculously cheap in my view. I expect that the stock can more than double over the next year.
Organigram Holdings Inc. Files Final Base Shelf Prospectus
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licenced producer of cannabis, announced today that it has obtained a receipt for a final short form base shelf prospectus (the “Base Shelf Prospectus”) filed with...
3 Marijuana Stocks To Buy In October 2023
Marijuana stock investors are keeping their eyes open for a chance to take profits. For some time the level of volatile trading has made it tough to do so. Although it has its pros and cons there has been a...
Organigram Holdings: Earnings Growth Set To Continue
Growing brands and strategic positioning show OGI's future potential. Having overcome recent challenges, OGI is positioned to thrive in the changing cannabis industry. The company's earnings estimates for 2024 are promising, and its strong balance sheet and strategic investments make...
Organigram Holdings Inc. Files Preliminary Base Shelf Prospectus
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licenced producer of cannabis, announced today that it has filed a preliminary short form base shelf prospectus (the “Base Shelf Prospectus”) with the securities commissions in...
Best Cannabis & Marijuana Stocks For Q3 2023
Marijuana stock investors are keeping focused on the future of the cannabis industry. Right now even with an increase in volatile trading, the industry is still progressing. There are more states and global regions that are working to establish legal...
Why Marijuana Stocks Triumphed on Monday
The House of Representatives is set to meet to discuss several pot-related measures this week. The march toward full U.S. legalization continues to gather pace.
Cannabis stock rally continues on marijuana rescheduling hopes
Cannabis stocks continued to move higher following the Labor Day long weekend after the U.S. Department of Health and Human Services (HHS) last week recommended reclassifying marijuana as a lower-risk drug.
Organigram Announces Resignation of Board Member
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announces today that Ms. Caroline Ferland has resigned from the Board of Directors (“the Board”) effective immediately. Ms. Ferland was a board...
Source: https://incomestatements.info
Category: Stock Reports